FDA Approves First CRISPR Gene Therapy for Sickle Cell Disease

Key Takeaways

• The FDA approved Casgevy (exagamglogene autotemcel) on December 8, 2023, as the first CRISPR/Cas9 gene therapy for any disease. Source: FDA
• In the CLIMB-121 trial, 97% of evaluable patients (29 of 30) achieved freedom from severe vaso-occlusive crises for at least 12 consecutive months. Source: NEJM
• Common adverse events include mucositis (84%), febrile neutropenia (69%), and decreased appetite (58%), consistent with myeloablative conditioning. Source: FDA Label
• The therapy requires specialized treatment centers; approximately 30-40 certified centers were planned for initial U.S. availability.

What Is Casgevy and How Does It Work?

Casgevy is an autologous gene therapy that uses CRISPR/Cas9 genome editing to modify a patient's own hematopoietic stem cells. The edited cells produce increased levels of fetal hemoglobin (HbF), which counteracts the sickling of red blood cells characteristic of sickle cell disease. This marks the first FDA-approved application of CRISPR gene editing technology in humans for any indication.

Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, the one-time infusion requires pretreatment with myeloablative conditioning to prepare the bone marrow for the edited stem cells. The manufacturing process involves collecting stem cells via apheresis, editing them ex vivo, and reinfusing them after conditioning.

What Efficacy Data Supported FDA Approval?

The FDA approval was based on data from the multicenter CLIMB-121 trial (NCT04208529), which enrolled 44 patients with severe sickle cell disease who had experienced at least two vaso-occlusive crises per year. Key findings included:

• Primary Endpoint: 29 of 30 evaluable patients (97%) achieved freedom from severe vaso-occlusive crises for at least 12 consecutive months
• Secondary Endpoint: All 30 evaluable patients (100%) achieved freedom from hospitalization for severe VOCs for at least 12 consecutive months
• Follow-up: Median follow-up was 19.3 months (range 0.8 to 48.1 months)
• Hemoglobin Response: Patients achieved fetal hemoglobin levels of 40% or higher and total hemoglobin at or near normal levels

Long-term follow-up data presented at the 2025 European Hematology Association meeting showed durable benefits, with some patients remaining VOC-free for up to 5.6 years post-treatment. The ongoing CLIMB-131 long-term follow-up study will monitor patients for up to 15 years.

What Is the Safety Profile of Casgevy?

The FDA has mandated a comprehensive safety monitoring program through a risk evaluation and mitigation strategy (REMS). The safety profile observed in clinical trials was consistent with myeloablative busulfan conditioning and autologous stem cell transplantation:

Common Adverse Events in CLIMB-121 Trial (≥40% of patients)

Adverse Event	Incidence
Mucositis	84%
Febrile neutropenia	69%
Decreased appetite	58%
Abdominal pain	47%
Nausea	47%

No cases of malignancy related to the gene editing were reported in the trial. One death occurred but was deemed unrelated to Casgevy treatment. The FDA label carries warnings about neutrophil engraftment failure, delayed platelet engraftment, and hypersensitivity reactions.

Who Is Eligible for Casgevy Treatment?

Casgevy is indicated for patients 12 years of age and older with sickle cell disease who have experienced recurrent vaso-occlusive crises. To be eligible, patients must:

1. Have sufficient hematopoietic stem cells for manufacturing
2. Be able to undergo myeloablative conditioning
3. Have adequate organ function for the procedure
4. Receive treatment at a certified healthcare facility enrolled in the Casgevy REMS program

The treatment process spans several months, including stem cell mobilization and collection, the 4-6 week manufacturing period, conditioning, and the reinfusion procedure.

What Did FDA Officials Say About the Approval?

Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, emphasized the significance of this milestone: "These approvals represent an important medical advance with the use of innovative cell-based gene therapies to target potentially devastating diseases and improve public health. Today's actions follow rigorous evaluations of the scientific and clinical data needed to support approval, reflecting the FDA's commitment to facilitating development of safe and effective treatments for conditions with severe impacts on human health." Source: FDA

When Will Casgevy Be Available?

Vertex Pharmaceuticals anticipated making Casgevy available at certified treatment centers beginning in early 2024. The company planned to initially support 30-40 specialized treatment centers across the United States capable of managing the complex administration process.

Industry analysts estimated the treatment cost at approximately $2.2 million per patient, reflecting the one-time curative potential compared with lifelong conventional management. Vertex has indicated it will work with payers to develop innovative payment models for the therapy.

What Is the Long-Term Follow-Up Plan?

Given the novel mechanism of CRISPR/Cas9 gene editing, the FDA required a 15-year long-term follow-up study (CLIMB-131) to monitor for delayed adverse events, including malignancies. All patients who receive Casgevy must enroll in this registry.

Vertex and CRISPR Therapeutics are also evaluating Casgevy for transfusion-dependent beta-thalassemia (approved by FDA on the same date) and pursuing regulatory approvals in Europe and other global markets. The European Medicines Agency granted conditional marketing authorization in January 2024.

Frequently Asked Questions

Primary Sources

1. U.S. Food and Drug Administration. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. Press Release. December 8, 2023.
2. New England Journal of Medicine. Exagamglogene Autotemcel for Sickle Cell Disease. Kanter J, et al. CLIMB-121 Trial Results. Published January 2024.
3. DailyMed (NIH). CASGEVY (exagamglogene autotemcel) Prescribing Information. FDA Label. December 2023.
4. ClinicalTrials.gov. Safety and Efficacy of CTX001 in Patients With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease (CLIMB-121). NCT04208529.
5. Vertex Pharmaceuticals Investor Relations. Vertex Presents Longer-Term Data at 2025 European Hematology Association Congress. June 2025.

Related Profiles

• Exagamglogene Autotemcel (Casgevy)
• Sickle Cell Disease
• Vertex Pharmaceuticals
• CRISPR Therapeutics

Related Coverage

• Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
• $2M Gene Therapy Cures Need a Financing Model
• FDA Approves Vertex's Journavx as First Non-Opioid Pain Drug for Acute Pain